Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
MorphoSys AG
MorphoSys AG
Activities:
Ingredients
X
LinkedIn
Trending Articles
Why smaller CDMOs should enhance their operational efficiency now: a CPHI expert guide
CPHI experts advise smaller CDMO's to invest in supply chain resilience, friend shoring and AI to keep up with the predicted uptick in funding for 2025
CPI collaborates with industry leaders to expedite drug manufacturing via digitisation
Digitising manufacturing technologies could allow enhanced ability to scale production, reduce costs and expedite the process
Adare expands global handling & packaging capabilities
The company will have enhanced compaction, milling, bin blending and tablet compression capabilities in Philadelphia, Ohio and Milan
Janssen to adopt Johnson & Johnson brand as the company celebrates 100 years of UK operation
The company's pharmaceutical and medical technology segments will combine under the Johnson & Johnson brand name in the UK
Making the most of each cell: single-use perfusion in biopharma processing
GEA kytero perfusion disk stack separators are pioneering the time- and cost-efficient harvesting of pharmaceutical proteins from cells and facilitating continuous processing,...
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Research & Development
MorphoSys and Immatics Biotechnologies sign immuno-oncology agreement
To develop antibody based therapies against multiple cancers
Research & Development
Merck Serono and MorphoSys agree immuno-oncology collaboration
MorphoSys\' Ylanthia antibody technology will be used to identify antibodies to fight tumours
Research & Development
MorphoSys and Heptares to develop antibody therapeutics targeting GPCRs
MorphoSys will apply Ylanthia library to develop products against StaRs from Heptares
Research & Development
MorphoSys expands 10-year antibody alliance with Novartis
Long-standing agreement will benefit from technologies not available in 2007
Ingredients
MorphoSys makes two management appointments
Charlotte Lohmann and Martin Clark join the German firm
Ingredients
MorphoSys unveils new antibody technology
Ylanthia will show higher success rates and shorter timelines in antibody drug development
Manufacturing
Boehringer signs manufacturing agreement with MorphoSys
Covers process development and manufacturing of clinical material for MOR208 antibody
Subscribe now